186 related articles for article (PubMed ID: 37044278)
21. Subconjunctival filtration in evolution: current evidence on MicroShunt implantation for treating patients with glaucoma.
Ahmed IIK; Sadruddin O; Panarelli JF
Eye Vis (Lond); 2023 Mar; 10(1):10. PubMed ID: 36859515
[TBL] [Abstract][Full Text] [Related]
22. One-year outcomes of microshunt implantation in pseudoexfoliation glaucoma.
Nobl M; Freissinger S; Kassumeh S; Priglinger S; Mackert MJ
PLoS One; 2021; 16(8):e0256670. PubMed ID: 34449795
[TBL] [Abstract][Full Text] [Related]
23. PRESERFLO™ MicroShunt versus trabeculectomy: first results on efficacy and safety.
Pillunat KR; Herber R; Haase MA; Jamke M; Jasper CS; Pillunat LE
Acta Ophthalmol; 2022 May; 100(3):e779-e790. PubMed ID: 34331505
[TBL] [Abstract][Full Text] [Related]
24. Device-modified trabeculectomy for glaucoma.
Park J; Rittiphairoj T; Wang X; E JY; Bicket AK
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD010472. PubMed ID: 36912740
[TBL] [Abstract][Full Text] [Related]
25. One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis.
Tanner A; Haddad F; Fajardo-Sanchez J; Nguyen E; Thong KX; Ah-Moye S; Perl N; Abu-Bakra M; Kulkarni A; Trikha S; Lascaratos G; Parnell M; Kailani O; King AJ; Agrawal P; Stead R; Giannouladis K; Rodrigues I; Goyal S; Hysi PG; Lim S; Yu-Wai-Man C
Br J Ophthalmol; 2023 Aug; 107(8):1104-1111. PubMed ID: 35365491
[TBL] [Abstract][Full Text] [Related]
26. Ab interno trabecular bypass surgery with Trabectome for open-angle glaucoma.
Hu K; Shah A; Virgili G; Bunce C; Gazzard G
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD011693. PubMed ID: 33580495
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.
Ibarz Barberá M; Martínez-Galdón F; Caballero-Magro E; Rodríguez-Piñero M; Tañá-Rivero P
J Glaucoma; 2022 Jul; 31(7):557-566. PubMed ID: 35583510
[TBL] [Abstract][Full Text] [Related]
28. Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery.
Cheng JW; Cheng SW; Wei RL; Lu GC
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009782. PubMed ID: 26769010
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors for Failure in Glaucoma Patients Undergoing Microshunt Implantation.
Rabiolo A; Toscani R; Sacchi M; Destefanis P; Bettin P; Ciampi C; Clemente A; Cutolo CA; Mercieca K; Iester M; Traverso CE; Di Maita M; Li Calzi G; Nucci P; Bandello F; Triolo G; De Cillà S
Am J Ophthalmol; 2024 Mar; 259():117-130. PubMed ID: 37979601
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of ab-interno gelatin microstent implantation in primary and refractory glaucoma.
Szigiato AA; Touma S; Jabbour S; Lord F; Agoumi Y; Singh H
Can J Ophthalmol; 2023 Aug; 58(4):328-337. PubMed ID: 35339436
[TBL] [Abstract][Full Text] [Related]
31. Trabeculectomy with or without mitomycin-C for paediatric glaucoma in aphakia and pseudophakia following congenital cataract surgery.
Mandal AK; Bagga H; Nutheti R; Gothwal VK; Nanda AK
Eye (Lond); 2003 Jan; 17(1):53-62. PubMed ID: 12579171
[TBL] [Abstract][Full Text] [Related]
32. PRESERFLO ™ MicroShunt versus trabeculectomy: 1-year results on efficacy and safety.
Jamke M; Herber R; Haase MA; Jasper CS; Pillunat LE; Pillunat KR
Graefes Arch Clin Exp Ophthalmol; 2023 Oct; 261(10):2901-2915. PubMed ID: 37133501
[TBL] [Abstract][Full Text] [Related]
33. Success rates of 2-site phacoemulsification combined with fornix-based trabeculectomy using mitomycin C for primary angle-closure glaucoma and primary open-angle glaucoma in an Asian population.
Koh V; Chen D; Aquino CM; Aduan J; Sng C; Chee LS; Chew P
Jpn J Ophthalmol; 2017 May; 61(3):245-252. PubMed ID: 28188405
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Management of Glaucoma in Phacomatosis Pigmentovascularis Over the Last Three Decades: A Single-Center Experience.
Mandal AK; Kodavati K; Gothwal VK
Ophthalmol Glaucoma; 2022; 5(1):101-109. PubMed ID: 34186220
[TBL] [Abstract][Full Text] [Related]
35. Prospective Randomized Trial Comparing Mitomycin C Combined with Ologen Implant versus Mitomycin C Alone as Adjuvants in Trabeculectomy.
Sen M; Midha N; Sidhu T; Angmo D; Sihota R; Dada T
Ophthalmol Glaucoma; 2018; 1(2):88-98. PubMed ID: 32677614
[TBL] [Abstract][Full Text] [Related]
36. The outcome of initial mitomycin C-augmented trabeculectomy with subconjunctival bevacizumab in the management of secondary glaucoma associated with Fuchs heterochromic iridocyclitis.
Elgin U; Sen E; Ozdemir K; Ozdal P; Berker N
Int Ophthalmol; 2020 Apr; 40(4):795-802. PubMed ID: 31792855
[TBL] [Abstract][Full Text] [Related]
37. Deep sclerectomy and trabeculectomy augmented with Mitomycin C: 2-year post-operative outcomes.
Dwivedi R; Somerville T; Cheeseman R; Rogers C; Batterbury M; Choudhary A
Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):1965-1974. PubMed ID: 33683432
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.
Grewal DS; Jain R; Kumar H; Grewal SP
Ophthalmology; 2008 Dec; 115(12):2141-2145.e2. PubMed ID: 18692246
[TBL] [Abstract][Full Text] [Related]
39. Fornix-based versus limbal-based conjunctival trabeculectomy flaps for glaucoma.
Theventhiran AB; Kim G; Yao W
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD009380. PubMed ID: 34437715
[TBL] [Abstract][Full Text] [Related]
40. Primary trabeculectomy with mitomycin C: safety and efficacy at 2 years.
Lusthaus JA; Kubay O; Karim R; Wechsler D; Booth F
Clin Exp Ophthalmol; 2010 Dec; 38(9):831-8. PubMed ID: 20572827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
